Two AstraZeneca breast cancer drugs are better than one
This article was originally published in Scrip
Executive Summary
Using a combination of AstraZeneca's aromatase inhibitor, anastrozole (Arimidex) with its oestrogen receptor modulator, Faslodex (fulvestrant) is more effective than either anastrozole alone or sequential anastrozole and fulvestrant in treating postmenopausal hormone-receptor (HR)–positive metastatic breast cancer, according to a newly published study.